NCT06215690

Brief Summary

The study will be conducted to examine the effects of abnormal growth pattern and cerebrovascular blood flow measurements on fetal frontal lobe development with the advancing ultrasound technology. Antenatal assessment of frontal lobe development will enable clinicians to predict neurodevelopmental problems that may develop postnatally. In addition, this study will examine the effects of FGR on frontal lobe development.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2023

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 15, 2023

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

December 22, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 22, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 4, 2024

Completed
16 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 20, 2024

Completed
Last Updated

July 8, 2024

Status Verified

July 1, 2024

Enrollment Period

1.1 years

First QC Date

December 22, 2023

Last Update Submit

July 4, 2024

Conditions

Keywords

Fetal Growth RestrictionAnterior Middle Brain StructuresCerebrovascular Flow

Outcome Measures

Primary Outcomes (1)

  • Ultrasonographic measurements and comparison of fetuses with and without fetal growth retardation

    Demographic data, ultrasonographically obtained biometric measurements, and Doppler flow data will be compared in both groups. * Frontal Anterior Posterior Length, Occipital to Frontal Diameter ratio mm/mm (FAPD mm/OFD mm) * Cerebellar length, head circumference length ratio mm/mm (CD mm / HC mm) The main biometric measurement of the study will be comparison. The percentile values of the Anterior Cerebral Artery Doppler Pulsatility Index (cm/s) (ACA PI cm/s ) and Middle Cerebral Artery Doppler Pulsatility Index cm/s (MCA PI cm/s) will be calculated for the week of ultrasonographic measurement, and the ratio of ACA PI and MCA PI will be compared in fetuses with and without fetal growth retardation.

    Prenatal (32-37 gestational weeks)

Secondary Outcomes (1)

  • Evaluation of neonatal findings of the patients included in the study

    through study completion, an average of 4 months

Study Arms (2)

Pregnant Women with Fetal Growth Restriction

Fetuses with fetal growth restriction according to Delphi consensus criteria between 32-37 weeks of gestation

Diagnostic Test: Ultrasound measurements

Healthy Pregnancies

Normally developing fetuses between 32-37 weeks of gestation

Diagnostic Test: Ultrasound measurements

Interventions

Evaluation will be performed by ultrasonography. The following measurements will be taken with the ultrasonographic examination. * BPD (Biparietal Diameter) * HC (Head Circumference) * AC (Abdominal Circumference) * FL (Femur Length) * EFW (Estimated Fetal Weight) * Umbilical Artery Doppler Sistole/Diastole (S/D) ,Pulsatility İndex (PI), Resistance İndex (RI) * Middle Cerebral Artery S/D,PI,RI * Uterine Artery Doppler PI * Anterior Cerebral Artery S/D,PI,RI * CPUR (Cerebral - Placental - Uterin PI Ratio) * CPR (Cerebral - Placental PI Ratio) * The deepest free single vertical pocket in the amnion mai * Cavum Septum Pellucidum: Width - Length Diameters * OFD (Occipitofrontal length) * FAPD (Frontal Anterior Posterior Diameter) * FAPD/OFD ratio * Cerebellar diameter * Lateral ventricle depth * Insular depth * Sylvian fissure depth

Healthy PregnanciesPregnant Women with Fetal Growth Restriction

Eligibility Criteria

Age32 Weeks - 37 Weeks
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

The study will include normally developing fetuses between 32-37 weeks of gestation and fetuses with fetal growth restriction.

You may qualify if:

  • Healthy hearts between the ages of 18-40
  • Singleton pregnancies
  • to 37 weeks gestational week range

You may not qualify if:

  • Multiple pregnancies
  • Fetuses with fetal karyotype abnormalities
  • Pregnant women with co-morbidity
  • Fetuses with fetal intracranial hemorrhage
  • Fetuses with cranial anomalies
  • Maternal obesity preventing measurement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Etlik City Hospital

Ankara, Yenimahalle, 06000, Turkey (Türkiye)

Location

Related Publications (1)

  • Ulusoy CO, Agaoglu RT, Sucu ST, Kurt DS, Bucak M, Seyhanli Z, Yucel KY. Evaluation of Anterior and Middle Brain Structures With Cerebrovascular Flow in Fetuses With Fetal Growth Restriction: A Prospective Study. J Clin Ultrasound. 2025 Feb;53(2):262-270. doi: 10.1002/jcu.23857. Epub 2024 Oct 8.

MeSH Terms

Conditions

Fetal Growth Retardation

Condition Hierarchy (Ancestors)

Fetal DiseasesPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGrowth DisordersPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 22, 2023

First Posted

January 22, 2024

Study Start

May 15, 2023

Primary Completion

July 4, 2024

Study Completion

July 20, 2024

Last Updated

July 8, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will not share

In accordance with hospital policy, it is not allowed to share data with third parties. If necessary, the chief researcher can be contacted

Locations